Skip to Main Content


The main pathology underlying the motor symptoms in Parkinson's disease (PD) is a rather selective degeneration of the nigrostriatal dopamine (DA) neuron system. The experimental strategies to restore brain function in PD patients have all been based on a very simple principle, namely, to replace the dead dopaminergic neurons by new, transplanted DA-producing cells. The interest in cell replacement dates back to the late 1970s when it was demonstrated that intrastriatal grafts of embryonic mesencephalic tissue, rich in DA neuroblasts, induced functional recovery in rats with neurotoxin-induced lesions of the nigrostriatal DA system. There is now a solid experimental basis showing functional efficacy of such transplantation to the striatum in animal models of PD, and a biological mechanism underlying the observed improvement, that is, restoration of striatal DA transmission.1,2 Extensive animal studies have shown that the grafted DA neurons display many of the morphological and functional characteristics of the intrinsic mesencephalic DA neurons: they reinnervate the denervated striatum and form synaptic contacts with host neurons, are spontaneously active and release DA, and receive afferent inputs from the host. Reinnervation by the grafts ameliorates several aspects of the DA deficiency syndrome in rodents and monkeys.


Based on these animal experimental data, clinical trials with transplantation of human embryonic mesencephalic tissue to the striatum in patients with PD were started in 1987. At that time, it was unknown whether cell replacement could work at all in the human brain. Therefore, the first phase of clinical transplantation research aimed at answering several basic scientific questions: first, can the grafted DA neurons survive and form connections? Second, can the patient's brain integrate and use the grafted DA neurons? Third, can the grafts induce a measurable clinical improvement in PD patients? So far, 300–400 patients with PD have been grafted with human embryonic mesencephalic tissue. The results have provided proof-of-principle that cell replacement can work in the PD patient's brain.


Besides transplantation of embryonic mesencephalic tissue, several other sources of cells secreting catecholamines have been tested clinically in PD patients. Intrastriatal implantation of tissue from the patient's own adrenal medulla was pioneered by Backlund and coworkers already in the early 1980s.3 These trials were the first attempts to apply the cell transplantation strategy to the human brain. The main interest in this approach arose in 1987, when dramatic improvements were described after adrenal medulla transplantation in PD patients using a new surgical technique.4 This report led to a large number of clinical trials. When the outcome in these studies had been evaluated, it was concluded that adrenal medulla transplantation can lead to modest improvement but with a serious level of mortality and morbidity5 and poor graft survival.6 Another approach has used autotransplantation of dopaminergic glomus cells from carotid body into the striatum of PD patients. An open-label trial showed modest mean improvement in operated patients and no direct positron emission tomography (PET) evidence for graft survival.7 Finally, ...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessPhysiotherapy Full Site: One-Year Subscription

Connect to the full suite of AccessPhysiotherapy content and resources including interactive NPTE review, more than 500 videos, Anatomy & Physiology Revealed, 20+ leading textbooks, and more.

$595 USD
Buy Now

Pay Per View: Timed Access to all of AccessPhysiotherapy

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.